Medtronic Inc. is consolidating its many divisions into a pair of operating groups and making changes to its management structure as part of is “One Medtronic” program.
The Minneapolis device giant said it will pull its cardiac rhythm disease management, cardiovascular and Physio‐Control businesses under one umbrella and unite its spinal and biologics, neuromodulation, diabetes, and surgical technologies units under another.
Chris O’Connell, formerly president of the diabetes segment, will lead the new spinal and biologics, neuromodulation, diabetes, and surgical technologies group as its president.
And an external search is under way for a new CRDM, cardiovascular and Physio‐Control group president.
Medtronic also said it made Jean‐Luc Butel president of its international operations and tapped Rick Kuntz as chief scientific, clinical and regulatory officer.